阿托伐他汀的基因多态性研究进展
投稿时间:2021-10-15  修订日期:2022-01-21  点此下载全文
引用本文:黄琴,索南格勒,李文斌,孙月梅,王荣.阿托伐他汀的基因多态性研究进展[J].药学实践杂志,2022,40(5):416~421,426
摘要点击次数: 106
全文下载次数: 113
作者单位E-mail
黄琴 中国人民解放军联勤保障部队第九四〇医院药剂科, 甘肃 兰州 730050
兰州大学药学院, 甘肃 兰州 730000 
 
索南格勒 青海省玉树州人民医院内科, 青海 玉树 815000  
李文斌 中国人民解放军联勤保障部队第九四〇医院药剂科, 甘肃 兰州 730050  
孙月梅 中国人民解放军联勤保障部队第九四〇医院药剂科, 甘肃 兰州 730050  
王荣 中国人民解放军联勤保障部队第九四〇医院药剂科, 甘肃 兰州 730050
兰州大学药学院, 甘肃 兰州 730000 
wangrong-69@163.com 
基金项目:国家自然科学基金(81673508);中央高校基本科研业务费专项(3192020009);甘肃省青年科技基金计划(20JR10RA014);医院院内应急医学科研项目(20yjky017)
中文摘要:阿托伐他汀是临床上广泛使用的调血脂药物,长期使用能够预防并减少动脉粥样硬化性心血管疾病(ASCVD)的发生,但阿托伐他汀的疗效具有显著的个体间差异,有些个体不能达到预期调脂目标值或出现严重的不良反应。这与个体间的遗传多样性有关,遗传变异可导致药物体内处置不同,从而导致临床疗效和不良反应有差异。对影响阿托伐他汀药物反应的药物代谢酶、药物转运体、药物作用靶点及与脂质代谢相关基因多态性加以综述,并从基因水平上探讨不同个体使用阿托伐他汀的药动学、药效学及不良反应易感性差别的原因。
中文关键词:阿托伐他汀  血脂  药物代谢酶  药物转运体  基因多态性
 
Research progress of atorvastatin gene polymorphism
Abstract:Atorvastatin is a blood lipid-lowering drug widely used clinically. Long-term use can prevent and reduce the occurrence of atherosclerotic cardiovascular disease (ASCVD). However, the efficacy of atorvastatin has significant inter-individual differences. Some individuals failed to achieve the expected lipid-lowering target value or had serious adverse reactions, which were related to the genetic diversity between individuals. Genetic variation can lead to differences in drug configuration, clinical efficacy and adverse reactions. The drug metabolism enzymes, drug transporters, drug targets and genetic polymorphisms related to lipid metabolism were reviewed in this paper that affect the drug response of atorvastatin, and from the gene level to explore the reasons for the differences in the pharmacokinetics, pharmacodynamics and susceptibility to adverse reactions of different individuals using atorvastatin.
keywords:atorvastatin  blood lipids  drug metabolizing enzymes  drug transporters  gene polymorphisms
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮